Neuraminidase Inhibitor - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511247668

Publication Date:

November 27, 2024

Pages:

104

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Influenza viruses are characterized by two surface glycoproteins i.e. hemagglutinnin and neuraminidase. Neuraminidase are the antigens which play an important role in defining the particular strain of influenza. Dosage and safety of neuraminidase inhibitors are the two main parameters, affecting the growth of neuraminidase inhibitors market. The various symptoms of influenza are cough, running nose, fever, headache, fatigue, chills etc. The neuraminidase are recommended for the treatment of the symptoms after the forty eight hours of start of these symptoms.
There are few neuraminidase inhibitors, being sold in the market. The neuraminidase inhibitors have been classified as zenamivir, oseltamivir, peramivir, leninamivir and few other neuraminidase inhibitors. Zenamivir and oseltamivir are the neuraminidase inhibitors which are being used for the treatment of influenza A or influenza B.
The global market for Neuraminidase Inhibitor was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Neuraminidase Inhibitor was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neuraminidase Inhibitor was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Neuraminidase Inhibitor was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, BioCryst and Daiichi Sankyo, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuraminidase Inhibitor, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Neuraminidase Inhibitor by region & country, by Type, and by Application.
The Neuraminidase Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuraminidase Inhibitor.
麻豆原创 Segmentation
By Company
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
BioCryst
Daiichi Sankyo
Segment by Type:
Zanamivir
Oseltamivir
Peramivir
Laninamivir
Segment by Application
Hospital Pharmacies
Drug Stores
Retail Stores
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neuraminidase Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Neuraminidase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Neuraminidase Inhibitor in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Neuraminidase Inhibitor Product Introduction
1.2 Global Neuraminidase Inhibitor 麻豆原创 Size Forecast
1.2.1 Global Neuraminidase Inhibitor Sales Value (2019-2030)
1.2.2 Global Neuraminidase Inhibitor Sales Volume (2019-2030)
1.2.3 Global Neuraminidase Inhibitor Sales Price (2019-2030)
1.3 Neuraminidase Inhibitor 麻豆原创 Trends & Drivers
1.3.1 Neuraminidase Inhibitor Industry Trends
1.3.2 Neuraminidase Inhibitor 麻豆原创 Drivers & Opportunity
1.3.3 Neuraminidase Inhibitor 麻豆原创 Challenges
1.3.4 Neuraminidase Inhibitor 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Neuraminidase Inhibitor Players Revenue Ranking (2023)
2.2 Global Neuraminidase Inhibitor Revenue by Company (2019-2024)
2.3 Global Neuraminidase Inhibitor Players Sales Volume Ranking (2023)
2.4 Global Neuraminidase Inhibitor Sales Volume by Company Players (2019-2024)
2.5 Global Neuraminidase Inhibitor Average Price by Company (2019-2024)
2.6 Key Manufacturers Neuraminidase Inhibitor Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Neuraminidase Inhibitor Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Neuraminidase Inhibitor
2.9 Neuraminidase Inhibitor 麻豆原创 Competitive Analysis
2.9.1 Neuraminidase Inhibitor 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Neuraminidase Inhibitor Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitor as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Zanamivir
3.1.2 Oseltamivir
3.1.3 Peramivir
3.1.4 Laninamivir
3.2 Global Neuraminidase Inhibitor Sales Value by Type
3.2.1 Global Neuraminidase Inhibitor Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Neuraminidase Inhibitor Sales Value, by Type (2019-2030)
3.2.3 Global Neuraminidase Inhibitor Sales Value, by Type (%) (2019-2030)
3.3 Global Neuraminidase Inhibitor Sales Volume by Type
3.3.1 Global Neuraminidase Inhibitor Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Neuraminidase Inhibitor Sales Volume, by Type (2019-2030)
3.3.3 Global Neuraminidase Inhibitor Sales Volume, by Type (%) (2019-2030)
3.4 Global Neuraminidase Inhibitor Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital Pharmacies
4.1.2 Drug Stores
4.1.3 Retail Stores
4.1.4 Others
4.2 Global Neuraminidase Inhibitor Sales Value by Application
4.2.1 Global Neuraminidase Inhibitor Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Neuraminidase Inhibitor Sales Value, by Application (2019-2030)
4.2.3 Global Neuraminidase Inhibitor Sales Value, by Application (%) (2019-2030)
4.3 Global Neuraminidase Inhibitor Sales Volume by Application
4.3.1 Global Neuraminidase Inhibitor Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Neuraminidase Inhibitor Sales Volume, by Application (2019-2030)
4.3.3 Global Neuraminidase Inhibitor Sales Volume, by Application (%) (2019-2030)
4.4 Global Neuraminidase Inhibitor Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Neuraminidase Inhibitor Sales Value by Region
5.1.1 Global Neuraminidase Inhibitor Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Neuraminidase Inhibitor Sales Value by Region (2019-2024)
5.1.3 Global Neuraminidase Inhibitor Sales Value by Region (2025-2030)
5.1.4 Global Neuraminidase Inhibitor Sales Value by Region (%), (2019-2030)
5.2 Global Neuraminidase Inhibitor Sales Volume by Region
5.2.1 Global Neuraminidase Inhibitor Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Neuraminidase Inhibitor Sales Volume by Region (2019-2024)
5.2.3 Global Neuraminidase Inhibitor Sales Volume by Region (2025-2030)
5.2.4 Global Neuraminidase Inhibitor Sales Volume by Region (%), (2019-2030)
5.3 Global Neuraminidase Inhibitor Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Neuraminidase Inhibitor Sales Value, 2019-2030
5.4.2 North America Neuraminidase Inhibitor Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Neuraminidase Inhibitor Sales Value, 2019-2030
5.5.2 Europe Neuraminidase Inhibitor Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Neuraminidase Inhibitor Sales Value, 2019-2030
5.6.2 Asia Pacific Neuraminidase Inhibitor Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Neuraminidase Inhibitor Sales Value, 2019-2030
5.7.2 South America Neuraminidase Inhibitor Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Neuraminidase Inhibitor Sales Value, 2019-2030
5.8.2 Middle East & Africa Neuraminidase Inhibitor Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Neuraminidase Inhibitor Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Neuraminidase Inhibitor Sales Value
6.2.1 Key Countries/Regions Neuraminidase Inhibitor Sales Value, 2019-2030
6.2.2 Key Countries/Regions Neuraminidase Inhibitor Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Neuraminidase Inhibitor Sales Value, 2019-2030
6.3.2 United States Neuraminidase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Neuraminidase Inhibitor Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Neuraminidase Inhibitor Sales Value, 2019-2030
6.4.2 Europe Neuraminidase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Neuraminidase Inhibitor Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Neuraminidase Inhibitor Sales Value, 2019-2030
6.5.2 China Neuraminidase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.5.3 China Neuraminidase Inhibitor Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Neuraminidase Inhibitor Sales Value, 2019-2030
6.6.2 Japan Neuraminidase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Neuraminidase Inhibitor Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Neuraminidase Inhibitor Sales Value, 2019-2030
6.7.2 South Korea Neuraminidase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Neuraminidase Inhibitor Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Neuraminidase Inhibitor Sales Value, 2019-2030
6.8.2 Southeast Asia Neuraminidase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Neuraminidase Inhibitor Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Neuraminidase Inhibitor Sales Value, 2019-2030
6.9.2 India Neuraminidase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.9.3 India Neuraminidase Inhibitor Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Information
7.1.2 GlaxoSmithKline Introduction and Business Overview
7.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
7.1.4 GlaxoSmithKline Neuraminidase Inhibitor Product Offerings
7.1.5 GlaxoSmithKline Recent Development
7.2 Gilead Sciences
7.2.1 Gilead Sciences Company Information
7.2.2 Gilead Sciences Introduction and Business Overview
7.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Gilead Sciences Neuraminidase Inhibitor Product Offerings
7.2.5 Gilead Sciences Recent Development
7.3 F. Hoffman-La Roche
7.3.1 F. Hoffman-La Roche Company Information
7.3.2 F. Hoffman-La Roche Introduction and Business Overview
7.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
7.3.4 F. Hoffman-La Roche Neuraminidase Inhibitor Product Offerings
7.3.5 F. Hoffman-La Roche Recent Development
7.4 BioCryst
7.4.1 BioCryst Company Information
7.4.2 BioCryst Introduction and Business Overview
7.4.3 BioCryst Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
7.4.4 BioCryst Neuraminidase Inhibitor Product Offerings
7.4.5 BioCryst Recent Development
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Company Information
7.5.2 Daiichi Sankyo Introduction and Business Overview
7.5.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Daiichi Sankyo Neuraminidase Inhibitor Product Offerings
7.5.5 Daiichi Sankyo Recent Development
8 Industry Chain Analysis
8.1 Neuraminidase Inhibitor Industrial Chain
8.2 Neuraminidase Inhibitor Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Neuraminidase Inhibitor Sales Model
8.5.2 Sales Channel
8.5.3 Neuraminidase Inhibitor Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
BioCryst
Daiichi Sankyo

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.